Influence of somatastatin on oral glucose tolerance in autonomous hypersecretion of growth hormone, prolactin or insulin (author's transl)

• Published in: Klinische Wochenschrift Vol. 53; no. 24; p. 1161
• Main Authors: Gottsmann, M, Landgraf, R, Londong, W, Werder, K
• Format: Journal Article
• Language: French; German
• Published: Germany 15-12-1975
• Subjects: Acromegaly - blood; Adenoma, Islet Cell - blood; Administration, Oral; Blood Glucose - analysis; Female; Gastrins - blood; Glucose - administration & dosage; Glucose - metabolism; Glucose Tolerance Test; Growth Hormone - blood; Humans; Insulin - blood; Male; Pituitary Neoplasms - blood; Prolactin - blood; Somatostatin - pharmacology; Time Factors
• ISSN: 0023-2173
• DOI: 10.1007/BF01476456

Oral glucose tolerance tests (OGTT) were performed for two subsequent days in 4 patients with active acromegaly, 2 patients with prolactin-producing pituitary adenomas and one insulinoma patient. Thirty minutes before the second OGTT 250 mug of somatostatin were injected intravenously as a bolus followed by a somatostatin infusion (500 mug) over 21/2 hours. The OGTTs were pathologic due to the hGH- and hPRL-induced insulin antagonism; they could not be normalized or improved by somatostatin. Only the peak of the blood sugar curve was shifted from one to two and a half hours after glucose administration; insulin and hGH levels were regularly suppressed after somatostatin whereas hPRL remained unchanged in most instances. Gastrin levels increased in all patients during the OGTT, the increase was suppressed in 4 patients. These findings show that the pathologic glucose tolerance due to insulin antagonism could not be improved by somatostatin in contrast to the deteriorated glucose tolerance in insulinopenic states.